Barinthus Biotherapeutics plc (BRNS) — Financial Flexibility Index

Latest as of September 2025: -0.44x

Barinthus Biotherapeutics plc (BRNS) has a Financial Flexibility Index of -0.44x as of September 2025. Free cash flow of $-10.73 Million (operating CF $-10.73 Million minus capex $0.00) represents 0% of total liabilities ($24.64 Million). Check asset allocation strategy of Barinthus Biotherapeutics plc to assess the company's strategic physical and investment asset allocation.

Financial Flexibility Index

-0.44x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-10.73 Million
Operating CF − Capex

Total Liabilities

$24.64 Million
USD

Capital Expenditures

$0.00
USD

Barinthus Biotherapeutics plc Financial Flexibility Index (2019–2024)

Historical Financial Flexibility Index trend for Barinthus Biotherapeutics plc across 6 annual periods. See Barinthus Biotherapeutics plc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Annual Financial Flexibility Index for Barinthus Biotherapeutics plc (2019–2024)

Year-by-year free cash flow to debt coverage for Barinthus Biotherapeutics plc. For the full company profile including market capitalisation, see Barinthus Biotherapeutics plc market capitalisation.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2024 -0.93x $-28.05 Million $-28.94 Million $30.19 Million ▲ +43.8%
2023 -1.65x $-45.51 Million $-50.92 Million $27.51 Million ▼ -438.7%
2022 -0.31x $-8.29 Million $-14.43 Million $27.00 Million ▲ +72.5%
2021 -1.12x $-31.44 Million $-32.58 Million $28.15 Million ▼ -459.8%
2020 -0.20x $-10.73 Million $-11.03 Million $53.81 Million ▲ +56.0%
2019 -0.45x $-18.63 Million $-18.76 Million $41.12 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities